BIOMAT Database Logo BIOMAT Database Logo

Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. 1996

P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
Department of Urology, St. Vincent's Hospital, University of New South Wales, Sydney, Australia.

OBJECTIVE Bacillus Calmette-Guérin (BCG) and interferon alpha-2b (IFN alpha 2b) have been used individually for the treatment of bladder cancer. We used a low dose of BCG combined with IFN alpha 2b to determine the safety and to assess the efficacy of this combination therapy. METHODS A study of 12 patients with superficial bladder cancer evaluated the safety and efficacy of a combination of low-dose BCG and IFN alpha 2b, given weekly for 6 weeks. Three patients were assigned to each of four groups in which 60 mg of BCG was combined with 10, 30, 60, or 100 x 10(6) IU of IFN alpha 2b. RESULTS The combination BCG/IFN alpha 2b therapy was well tolerated, with adverse effects being mild to moderate and resolved at the end of treatment. At 12 months post-treatment there has been no tumor progression. Two patients with previous multifocal transitional cell carcinoma have had solitary recurrences. One patient has had recurrent carcinoma in situ. CONCLUSIONS This preliminary study found combination BCG/IFN alpha 2b induction therapy to be safe and well tolerated. These early results show a high response rate, but efficacy can only be determined with Phase II and III studies.

UI MeSH Term Description Entries
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000283 Administration, Intravesical The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms. Bladder Drug Administration,Drug Administration, Bladder,Instillation, Bladder,Intravesical Drug Administration,Administration, Intravesical Drug,Injections, Intravesical,Intravesical Administration,Intravesical Injection,Intravesical Instillation,Administration, Bladder Drug,Administrations, Bladder Drug,Administrations, Intravesical,Administrations, Intravesical Drug,Bladder Drug Administrations,Bladder Instillation,Bladder Instillations,Drug Administration, Intravesical,Drug Administrations, Bladder,Drug Administrations, Intravesical,Injection, Intravesical,Instillation, Intravesical,Instillations, Bladder,Instillations, Intravesical,Intravesical Administrations,Intravesical Drug Administrations,Intravesical Injections,Intravesical Instillations

Related Publications

P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
March 2017, The Cochrane database of systematic reviews,
P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
January 2008, Urologia internationalis,
P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
October 2001, The Journal of urology,
P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
Intravesical Bacillus Calmette-Guérin treatment for superficial bladder tumours.
June 1989, British journal of urology,
P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
[Intravesical bacillus Calmette-Guérin therapy for superficial bladder tumors].
October 1987, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.
November 2010, The Journal of urology,
P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer.
January 1990, International urology and nephrology,
P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer.
January 2000, Urologia internationalis,
P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
Experience with bacillus Calmette-Guérin in patients with superficial bladder tumors. Value of monocyte activation in intravesical bacillus Calmette-Guérin therapy.
January 1987, European urology,
P Stricker, and K Pryor, and T Nicholson, and D Goldstein, and D Golovsky, and R Ferguson, and P Nash, and S Ehsman, and J Rumma, and G Mammen, and R Penny
[Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer : Comment on a recently published Cochrane Review].
August 2017, Der Urologe. Ausg. A,
Copied contents to your clipboard!